A Perspective on Incentives for Novel Inpatient Antibiotics: No One-Size-Fits-All

Taimur Bhatti¹, Ka Lum¹, Silas Holland¹+3

• ¹Taimur Bhatti, M.Sc., is an International Payer Strategy Leader at Hoffmann-La Roche and holds a Bachelor of Science in Biomedical Engineering from Duke University and a Master in Science in Pharmaceutical Sciences from the University of Toronto (Canada). Ka Lum, Ph.D., M.B.A., was Head of Immunology, Ophthalmology and Infectious Diseases, Global Pricing & Market Access, at Genentech, a member of the Roche Group, based in South San Francisco, California, and received her Ph.D. in Chemistry from UC Berkeley and an M.B.A. from UC Berkeley. Silas Holland, M.P.H., M.A., is a Director of Global Public Policy at Merck and Co., Inc., in Kenilworth, New Jersey, and holds a Bachelor of Science in Biology from Duke University and postgraduate degrees in education (Loyola Marymount University) and public health (University of Pretoria, South Africa). Stephanie Sassman is a Lifecycle Leader in Immunology at Genentech, a member of the Roche Group, based in South San Francisco, California and holds a Bachelor of Business Administration from the University of Texas at Austin. David Findlay, M.B.A., was a Global Commercial Director for anti-infectives at GSK and has a B.Sc. in Experimental Psychology from Reading University and an M.B.A. specializing in international business strategy from the University of Bradford's Management Centre. Kevin Outterson, J.D., LL.M., is a Professor of Law at Boston University School of Law and Executive Director/Principal Investigator of CARB-X. He holds a J.D. from Northwestern University, Chicago, Illinois and an LL.M. from the University of Cambridge, UK.